USAResearch and clinical trials
In babies with galactosemia, early speech support was more effective than usual care
Speech and language problems are common in galactosemia.
Inborn errors of metabolism
An inherited problem with processing sugar. The body cannot use galactose, a sugar found in milk. If not treated, severe liver problems begin in the baby in the first days.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
Orphanet has a guideline for emergency doctors for this disease (language: French). See on Orphanet
This page is translated from the Turkish original.
This disease is followed through the “Inborn errors of metabolism” group.
Galactose is part of milk sugar. It is found in breast milk and dairy products. In this disease, the enzyme that breaks down galactose hardly works at all. Galactose and its by-products build up and damage the liver, brain, eyes and kidneys.
The baby looks healthy at birth. Once the baby starts having milk, symptoms can appear within a few days.
In many countries, it is found through newborn heel-prick screening. Enzyme activity and galactose products are measured in red blood cells. The diagnosis is supported by a genetic test.
The most important step is to start a diet without milk sugar right away. Instead of breast milk and regular formula, a galactose-free formula is given. The diet is lifelong. Speech therapy, educational support and hormone support may be needed. Development and the eyes are checked regularly. New medicines specific to the disease are being researched. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through recessive inheritance. The mother and father are usually healthy carriers. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. When relatives marry, the chance that two carriers have children together is higher. Genetic counselling guides the family.
Source: MedlinePlus Genetics: Galactosemia · NORD: Galactosemia
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
We could not find a patient association specific to this disease.
For all rare diseases: Nadir Hastalıklar Federasyonu
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
USAResearch and clinical trials
Speech and language problems are common in galactosemia.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
ClinicalTrials.gov currently lists no active interventional studies for this disease. Last checked: October 7, 2026.
See all studies on ClinicalTrials.gov · Joining clinical trials
EUNew treatments and approvals
In Europe, leriglitazone, taken by mouth, was authorized for cerebral adrenoleukodystrophy.
USANew treatments and approvals
Through the accelerated pathway, the FDA has approved pariglasgene brecaparvovec for glycogen storage disease type Ia.
EuropeResearch and clinical trials
A total of 58 patients from 34 centers in seven European countries were followed.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:79239 · ICD-11 5C51.40
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.